The week in health tech, explained in plain English.Get the free newsletter →
September 21, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

The Hidden Costs Buried in Healthcare Payment Operations

Healthcare organizations chronically underestimate what it costs to move money, according to Healthcare Dive. The reason is structural: the true cost of payment operations does not sit in one place. It is scattered across four separate budgets, which means no single owner or line item ever captures the full number.

That fragmentation hides real spending. Paper checks, manual reconciliation, printing and mailing, staff time chasing exceptions, and the overhead of managing multiple payment channels all get booked in different departments. Added together, the total is far larger than most finance leaders assume when they look at any one budget.

The practical takeaway for operators is to stop evaluating payment costs department by department and start measuring the end-to-end process. Consolidating and automating payments can shrink manual work and errors, but the case for change only becomes visible once the scattered costs are summed. Until leaders add up all four budgets, the savings opportunity stays invisible.

More in Finance

Finance

Alkermes Orexin Agonist Shows Early Promise in ADHD

Alkermes reported that its orexin agonist showed early potential to treat ADHD, the first promise the drug class has shown for the condition.

Why it matters: A non-stimulant, novel-mechanism ADHD therapy could reshape a market long dominated by stimulants with abuse and shortage risks.

Finance

FDA Approves First Sanfilippo Gene Therapy From Ultragenyx

The FDA approved Ultragenyx's Fayuvi as the first therapy targeting the underlying cause of Sanfilippo syndrome type A.

Why it matters: It gives children with an ultra-rare, fatal neurological disorder their first approved treatment aimed at the disease's root cause.

Finance

Definium's LSD Therapy Eases Anxiety in Second Large Trial

Definium said its LSD-based therapy reduced anxiety in a second large trial, advancing the psychedelic drug class toward regulatory approval.

Why it matters: Positive late-stage data pushes psychedelic medicine closer to its first approvals, signaling a potential new category of fast-acting mental-health treatments.